Sézary syndrome (SS) is a rare and aggressive CD4+ leukemic variant of cutaneous T cell lymphoma (CTCL) with a disease-specific 5-year survival of 36% and median survival of 2–4 years [1]. This evidence concerns the gene CD4 and synovial sarcoma.